Literature DB >> 16963746

Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.

Andrew I Bell1, Katherine Groves, Gemma L Kelly, Debbie Croom-Carter, Edwin Hui, Anthony T C Chan, Alan B Rickinson.   

Abstract

Studies of Epstein-Barr virus (EBV)-positive cell lines have identified several forms of virus latency, but the patterns of virus gene expression in EBV-positive tumour cells appear more variable. However, it is unclear to what extent these differences merely reflect the increased sensitivities of different detection methods. Here, the design and validation of novel real-time RT-PCR assays to quantify relative levels of EBV transcripts are described. When the new assays were used to screen a collection of endemic Burkitt's lymphoma tumours, abundant Qp-driven EBNA1 expression was found, whereas the other latent transcripts (with the exception of LMP2A) were either absent or detectable only at trace levels. Analysis of 12 nasopharyngeal carcinoma biopsies revealed significant levels of EBNA1 and LMP2A transcripts in almost every case but, in contrast to previous reports, LMP1 expression was undetectable. These new quantitative assays may help to provide a clearer picture of EBV gene expression in tumour material.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963746     DOI: 10.1099/vir.0.81906-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  68 in total

1.  The nucleotide polymorphisms within the Epstein-Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro.

Authors:  Feng-Wei Wang; Xian-Rui Wu; Wen-Ju Liu; Ying-Jie Liang; Yu-Fan Huang; Yi-Ji Liao; Chun-Kui Shao; Yong-Sheng Zong; Shi-Juan Mai; Dan Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-07       Impact factor: 2.503

2.  Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.

Authors:  Isabel A Hutchings; Rosemary J Tierney; Gemma L Kelly; Julianna Stylianou; Alan B Rickinson; Andrew I Bell
Journal:  J Virol       Date:  2006-08-18       Impact factor: 5.103

3.  Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors:  Osman Cen; Richard Longnecker
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

4.  The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes.

Authors:  Regina Feederle; Janina Haar; Katharina Bernhardt; Sarah D Linnstaedt; Helmut Bannert; Helge Lips; Bryan R Cullen; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

5.  An auto-regulatory loop for EBV LMP2A involves activation of Notch.

Authors:  Leah J Anderson; Richard Longnecker
Journal:  Virology       Date:  2007-11-05       Impact factor: 3.616

6.  Modulation of LMP1 protein expression by EBV-encoded microRNAs.

Authors:  Angela Kwok Fung Lo; Ka Fai To; Kwok Wai Lo; Raymond Wai Ming Lung; Jan Wai Ying Hui; Gangling Liao; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

7.  Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.

Authors:  Christoph Mancao; Wolfgang Hammerschmidt
Journal:  Blood       Date:  2007-08-06       Impact factor: 22.113

8.  Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.

Authors:  Pegah Johansson; Ann Jansson; Ulla Rüetschi; Lars Rymo
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

9.  The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene.

Authors:  Pegah Johansson; Ann Jansson; Ulla Rüetschi; Lars Rymo
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

10.  Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.

Authors:  R Bultema; R Longnecker; M Swanson-Mungerson
Journal:  Oncogene       Date:  2009-02-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.